# Manning Family Foundation

> Manning Family Foundation is a VC fund backing Health Care, Therapeutics and Genetics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Apr 2025
- Lead investor: 0%
- Last updated: Aug 2026

Manning Family Foundation is a VC fund focused on Health Care and Therapeutics. Manning Family Foundation

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Therapeutics | 2 | 67% |
| Genetics | 1 | 33% |
| Wellness | 1 | 33% |
| Biopharma | 1 | 33% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |
| Series C | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Atsena Therapeutics | Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases. Their clinical programs include therapies for X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Atsena utilizes an adeno-associated virus (AAV) technology platform, including a novelspreading capsid (AAV.SPR), to target specific retinal conditions. Their ongoing research aims to prevent blindness caused by genetic mutations and is powered by their innovative approach to ocular gene therapy. | $150M | Series C | Apr 02, 2025 | https://atsenatx.com/ |
| Opus Genetics | Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The company's pipeline includes gene therapies based on adeno-associated virus (AAV) aimed at treating inherited retinal conditionssuch as Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its leading candidate, OPGx-LCA5, is currently in a Phase 1/2 trial for mutations related to LCA5 and has displayed promising early outcomes. Other initiatives encompass OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration, as well as a small molecule therapy for diabetic retinopathy that is ready for Phase 3, which has been developed under a Special Protocol Assessment with the FDA. | $19M | Seed | Sep 22, 2021 | http://opusgtx.com/ |
| Atsena Therapeutics | Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases. Their clinical programs include therapies for X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Atsena utilizes an adeno-associated virus (AAV) technology platform, including a novelspreading capsid (AAV.SPR), to target specific retinal conditions. Their ongoing research aims to prevent blindness caused by genetic mutations and is powered by their innovative approach to ocular gene therapy. | $55M | Series A | Dec 16, 2020 | https://atsenatx.com/ |

3 of 3 investments shown.

## Co-investors
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 2 deals together
- [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners) — VC Fund, 2 deals together
- [Lightstone Ventures](https://shizune.co/investors/profile/lightstone-ventures) — VC Fund, 2 deals together
- [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners) — VC Fund, 2 deals together
- Retinal Degeneration Fund — VC Fund, 2 deals together
- [Sofinnova Investments](https://shizune.co/investors/profile/sofinnova-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Manning Family Foundation invest in?

Manning Family Foundation invests primarily in Health Care, Therapeutics and Genetics startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Manning Family Foundation last invest?

The most recent investment recorded for Manning Family Foundation closed in Apr 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co